ImageneBio Seeks Shareholder Approval for 7.6% Expansion of Equity Incentive Plan
IMA sits 53% above its 52-week low of $3.94 on light trading volume (0.1× avg).
Summary
ImageneBio filed definitive additional proxy materials for its upcoming annual meeting, seeking shareholder approval to increase its equity incentive plan by 850,000 shares, representing a potential 7.6% dilution.
Key Events · Corporate Governance and Compliance · IMA
-
Proposed Equity Incentive Plan Expansion
ImageneBio is seeking shareholder approval to amend and restate its 2025 Equity Incentive Plan, increasing the aggregate number of shares authorized for issuance by 850,000 shares. This proposed increase represents a potential future dilution of approximately 7.6% of the company's current market capitalization.
-
Annual Meeting Scheduled
The company's annual stockholder meeting is scheduled for June 16, 2026, where shareholders will vote on the proposed equity plan expansion, director elections, and auditor ratification.
-
Director Elections
Shareholders will vote on the election of two Class II directors, David P. Bonita, M.D. and Joseph P. Slattery, to hold office until the 2029 Annual Meeting.
-
Auditor Ratification
The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, is up for shareholder ratification.
Analysis · IMA · Life Sciences
ImageneBio is proposing a significant increase to its 2025 Equity Incentive Plan, adding 850,000 shares for issuance. This represents a potential future dilution of approximately 7.6% based on the company's current market capitalization. While equity incentive plans are crucial for attracting and retaining talent, this substantial increase could impact existing shareholder value. Investors should consider the long-term benefits of incentivizing employees against the dilutive effect.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMA was trading at $6.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $3.94 to $216.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.